Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study
Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak – 18 May 2022
Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak – 18 May 2022
María Crespo, Ivana Nikolic, Alfonso Mora, Elena Rodríguez, Luis Leiva‐Vega, Aránzazu Pintor‐Chocano, Daniel Horrillo, Lourdes Hernández‐Cosido, Jorge L. Torres, Eva Novoa, Rubén Nogueiras, Gema Medina‐Gómez, Miguel Marcos, Magdalena Leiva, Guadalupe Sabio – 18 May 2022 – Obesity features excessive fat accumulation in several body tissues and induces a state of chronic low‐grade inflammation that contributes to the development of diabetes, steatosis, and insulin resistance.
Yooyun Chung, Michael A. Heneghan – 18 May 2022
Gad Asher, Bokai Zhu – 18 May 2022 – The mammalian liver must cope with various metabolic and physiological changes that normally recur every day and primarily stem from daily cycles of rest‐activity and fasting‐feeding. Although a large body of evidence supports the reciprocal regulation of circadian rhythms and liver function, the research on the hepatic ultradian rhythms have largely been lagging behind.
AASLD’s bylaws were approved in 2020 and updated in October 2023.
The Associate Fellow of the AASLD is dedicated to promoting Associates and their delivery of specialized and high-quality health care.
Cumali Efe, Tuğrul Purnak – 17 May 2022
Guillaume Rossignol, Xavier Muller, Valérie Hervieu, Sophie Collardeau‐Frachon, Antoine Breton, Natacha Boulanger, Mickaël Lesurtel, Rémi Dubois, Kayvan Mohkam, Jean‐Yves Mabrut – 17 May 2022 – Partial liver grafts from ex situ splitting are considered marginal due to prolonged static cold storage. The use of ex situ hypothermic oxygenated perfusion (HOPE) may offer a strategy to improve preservation of ex situ split grafts.
Rahil H. Shah, Darius Chyou, David S. Goldberg – 17 May 2022 – Since its inception in 2002, Model for End‐Stage Liver Disease (MELD)–based allocation has undergone a series of revisions, especially with respect to exception points. Hepatocellular carcinoma (HCC) is the most common indication for MELD exceptions, and as a result of higher transplant proportions and lower waitlist mortality, a series of policy changes have been implemented to deprioritize HCC transplants. We examined the impact of HCC exception policy changes on transplant and waitlist mortality rates.